Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
44.11 USD | -5.69% | -7.35% | +98.07% |
Financials (USD)
Sales 2024 * | 43.19M | Sales 2025 * | 125M | Capitalization | 2.66B |
---|---|---|---|---|---|
Net income 2024 * | 71M | Net income 2025 * | -342M | EV / Sales 2024 * | 59.7 x |
Net cash position 2024 * | 76.75M | Net cash position 2025 * | 15.43M | EV / Sales 2025 * | 21.1 x |
P/E ratio 2024 * |
41.2
x | P/E ratio 2025 * |
-7.85
x | Employees | 385 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 76.63% |
Latest transcript on Agios Pharmaceuticals, Inc.
1 day | -5.69% | ||
1 week | -7.72% | ||
Current month | +21.38% | ||
1 month | +31.51% | ||
3 months | +47.03% | ||
6 months | +93.80% | ||
Current year | +98.07% |
Managers | Title | Age | Since |
---|---|---|---|
Brian Goff
CEO | Chief Executive Officer | 55 | 22-08-07 |
Cecilia Jones
DFI | Director of Finance/CFO | 49 | 22-09-25 |
Jacqualyn Fouse
CHM | Chairman | 62 | 17-12-04 |
Members of the board | Title | Age | Since |
---|---|---|---|
Jeffrey Capello
BRD | Director/Board Member | 69 | 23-05-31 |
Director/Board Member | 64 | 14-12-08 | |
May Kin Ho
BRD | Director/Board Member | 71 | 15-06-22 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
4.52% | 1 M€ | +0.84% | - | |
0.16% | 0 M€ | 0.00% | - | |
0.14% | 0 M€ | 0.00% | - | |
0.06% | 415 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-06-14 | 44.11 | -5.69% | 804,770 |
24-06-13 | 46.77 | -2.50% | 647,833 |
24-06-12 | 47.97 | +0.97% | 1,138,122 |
24-06-11 | 47.51 | +0.61% | 557,747 |
24-06-10 | 47.22 | -0.82% | 587,372 |
Delayed Quote Nasdaq, June 14, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+98.07% | 2.66B | |
+18.15% | 124B | |
+18.02% | 111B | |
-12.75% | 23.17B | |
+5.07% | 22.94B | |
-39.94% | 17.42B | |
-9.86% | 17.42B | |
-14.97% | 16.9B | |
+2.80% | 13.71B | |
+27.39% | 11.82B |
- Stock Market
- Equities
- AGIO Stock